About Transmembrane protein 184B
Transmembrane protein 184B (TMEM184B) is a protein
from Homo sapiens identified by UniProt accession
Q9Y519, 407 residues long.
MolForge cross-references it against 0 known binders and
58 disease associations.
Target properties
| Protein name | Transmembrane protein 184B |
|---|
| UniProt accession | Q9Y519 |
|---|
| Gene | TMEM184B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 407 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (58)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.35
- mammographic density measurement · score 0.32
- BMI-adjusted waist circumference · score 0.31
- mammographic density percentage · score 0.25
- dense area measurement · score 0.25
- Mental deterioration · score 0.14
- lean body mass · score 0.05
- body weight · score 0.05
- hemoglobin measurement · score 0.04
- spinal muscular atrophy, type IV · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9Y519-F1 | alphafold | PREDICTED | 72.68 | — |
Amino-acid sequence (407 residues)
MTVRGDVLAP DPASPTTAAA SPSVSVIPEG SPTAMEQPVF LMTTAAQAIS GFFVWTALLI TCHQIYMHLR CYSCPNEQRY IVRILFIVPI YAFDSWLSLL FFTNDQYYVY FGTVRDCYEA LVIYNFLSLC YEYLGGESSI MSEIRGKPIE SSCMYGTCCL WGKTYSIGFL RFCKQATLQF CVVKPLMAVS TVVLQAFGKY RDGDFDVTSG YLYVTIIYNI SVSLALYALF LFYFATRELL SPYSPVLKFF MVKSVIFLSF WQGMLLAILE KCGAIPKIHS ARVSVGEGTV AAGYQDFIIC VEMFFAALAL RHAFTYKVYA DKRLDAQGRC APMKSISSSL KETMNPHDIV QDAIHNFSPA YQQYTQQSTL EPGPTWRGGA HGLSRSHSLS GARDNEKTLL LSSDDEF
Explore Transmembrane protein 184B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets